Evaluating Alternative Ramucirumab Doses as a Single Agent or with Paclitaxel in Second-Line Treatment of Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma: Results from Two Randomized, Open-Label, Phase II Studies.
angiogenesis
gastric adenocarcinoma
ramucirumab
vascular endothelial growth factor receptor
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
24 Feb 2022
24 Feb 2022
Historique:
received:
23
12
2021
revised:
03
02
2022
accepted:
05
02
2022
entrez:
10
3
2022
pubmed:
11
3
2022
medline:
11
3
2022
Statut:
epublish
Résumé
Studies JVDB and JVCZ examined alternative ramucirumab dosing regimens as monotherapy or combined with paclitaxel, respectively, in patients with advanced/metastatic gastric/gastroesophageal junction (GEJ) adenocarcinoma. For JVDB, randomized patients (
Identifiants
pubmed: 35267477
pii: cancers14051168
doi: 10.3390/cancers14051168
pmc: PMC8909008
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Eli Lilly and Company, USA
ID : N/A
Références
J Clin Oncol. 2010 Feb 10;28(5):780-7
pubmed: 20048182
J Clin Oncol. 2015 Jun 10;33(17):1889-94
pubmed: 25667295
J Clin Oncol. 2017 Aug 1;35(22):2558-2567
pubmed: 28574779
Lancet. 2014 Jan 4;383(9911):31-39
pubmed: 24094768
Lancet Oncol. 2017 May;18(5):558-559
pubmed: 28359785
J Clin Oncol. 2004 Jun 1;22(11):2184-91
pubmed: 15169807
Clin Cancer Res. 2018 Dec 1;24(23):5841-5849
pubmed: 29891725
Lancet Oncol. 2017 May;18(5):611-622
pubmed: 28359784
Lancet. 2014 Aug 23;384(9944):665-73
pubmed: 24933332
Lancet Oncol. 2014 Oct;15(11):1224-35
pubmed: 25240821
Ann Oncol. 2017 Dec 1;28(12):2932-2942
pubmed: 28950290
Mol Cancer Ther. 2017 Oct;16(10):2215-2222
pubmed: 28716815
Lancet Oncol. 2019 Feb;20(2):282-296
pubmed: 30665869
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Lancet. 2017 Nov 18;390(10109):2266-2277
pubmed: 28916371
Br J Clin Pharmacol. 2017 Dec;83(12):2741-2751
pubmed: 28833321